Recently, the 63rd National Pharmaceutical Machinery Expo and the 2023 (Autumn) China International Pharmaceutical Machinery Expo (CIPM) were grandly held in Xiamen. At the same time as this year's pharmaceutical machinery exhibition, Dr. Chen Ping, Director, Vice President, and Chief Technology Officer of TIANS, was interviewed by CIPM. He elaborated on the characteristics of TIANS’T-EPC model and how to help pharmaceutical companies cross the "valley of death" from laboratory to industrialization. At the same time, he also shared the growth process of the cooperation between Tiangushi Group and Pharmaceutical Machinery Exhibition over the past few decades, expressed gratitude for the open, equal, and professional display platform provided by Pharmaceutical Machinery Exhibition, and looked forward to future cooperation between the two sides in multiple aspects and channels.

Video | Dr. Chen Ping Accepts CIPM Interview

The PRO version of traditional EPC in T-EPC mode

The EPC (Engineering Procurement Construction) engineering general contracting model has the advantages of solving the contradiction of mutual constraints and disconnection between design, procurement, and construction, so that each link can be carried out and implemented intermittently, effectively reducing the construction cycle and ensuring good investment benefits. The T-EPC model created by TIANShas added a technology leadership (T) module on the basis of the EPC model. It focuses on process technology and design, features system integration optimization, and aims to achieve one-time trial production success. This helps to promote the industrialization of innovative technologies and help pharmaceutical companies achieve a leap from research and development to industrialization.

Firstly, the process technology in the T-EPC mode runs through the entire process to ensure the implementation of the project. By building a powerful technical platform and deploying numerous professional technical personnel,TIANS can have a good understanding and optimization of production processes. Process technology and design experts run through the entire project process, ensuring the rationality, economic applicability, and engineering feasibility of the project from the source and throughout the implementation process, and quickly and effectively helping the project land. At the same time, it reduces the investment of the owner's project team and reduces project risks.TIANShas achieved uniqueness in the EPC field.

Picture | TIANS Pharmaceutical Machinery Exhibition

Secondly, high-quality design reduces total investment. Quality comes from design, and design determines project investment. TIANS Design has two major platforms, the Swiss Biomedical Consulting and Innovation Center and the Chinese Local Design Institute. The design team has rich experience in production management, engineering design, and construction. During the design process, they can consider production processes, construction processes, and environmental protection processes in parallel, with a forward thinking approach, helping clients achieve comprehensive assurance of solutions, investment, progress, and project quality. At the same time, TIANS with its first-class BIM team, can provide engineering digital solutions for pharmaceutical enterprises, visually display project results, simulate and optimize production scenarios, optimize construction plans, control engineering investment, reduce construction risks, and provide guarantees for later operation and maintenance.

Picture | Explanation by design and technical experts from TIANS Group

Crossing the Valley of Death to Accelerate Industry Landing

In the pharmaceutical industry, the development of new drugs from laboratory to industrialization involves various stages such as laboratory process technology development, pilot scale up and validation, engineering design and construction, and factory production and sales. In this process, there is a concept of "death valley": that is, the scientific research achievements obtained from the laboratory stage cannot overcome the various problems faced by small-scale, pilot, and mass production due to the lack of industrialization experience, Resulting in the inability to form commercialized products.

Why can TIANS help customers achieve a leap of faith from laboratory to industrialization? Because the value chain of TIANS extends before and after traditional EPC services. The service content includes pre project consultation, planning, improvement and optimization of process packages, post project debugging and verification, and ultimately delivery of qualified products. In the early stage of process development, Tiangushi has experts from various industries such as medicine, chemical industry, automation and information technology, and environmental protection. They are familiar with production processes, understand design laws and regulations, and the latest design concepts, and can help customers improve their processes; During the later trial production process, TIANS will select technical experts to establish a system trial production team, which will participate in the trial production work in a full process and all aspects, ensuring that with the on-site guidance of technical experts, the trial production cycle is reasonably shortened, and the project can be put into operation as soon as possible.

Ten years of companionship, starting a new chapter in the future

The past decade has been a decade of continuous iteration, upgrading, and rapid development in the pharmaceutical industry, as well as a decade jointly passed by TIANS and Pharmaceutical Machinery Exhibition. From 2013 to 2023, Tiangushi showcased its product characteristics, technological innovation, and solution advantages through the platform of the Pharmaceutical Machinery Exhibition. The multiple online and offline forums jointly organized by the two sides have benefited nearly 10000 viewers. In the future, we hope to further deepen our cooperation with the pharmaceutical machinery exhibition and jointly promote the progress and development of the pharmaceutical industry.

Picture | Dr. Chen Ping shares at the International Forum of the Pharmaceutical Machinery Exhibition